The immune response to SARS-CoV-2 in people with HIV. Höft, M. A, Burgers, W. A, & Riou, C. Cellular & Molecular Immunology, Nature Publishing Group, oct, 2023. ![The immune response to SARS-CoV-2 in people with HIV [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex This review examines the intersection of the HIV and SARS-CoV-2 pandemics. People with HIV (PWH) are a heterogeneous group that differ in their degree of immune suppression, immune reconstitution, and viral control. While COVID-19 in those with well-controlled HIV infection poses no greater risk than that for HIV-uninfected individuals, people with advanced HIV disease are more vulnerable to poor COVID-19 outcomes. COVID-19 vaccines are effective and well tolerated in the majority of PWH, though reduced vaccine efficacy, breakthrough infections and faster waning of vaccine effectiveness have been demonstrated in PWH. This is likely a result of suboptimal humoral and cellular immune responses after vaccination. People with advanced HIV may also experience prolonged infection that may give rise to new epidemiologically significant variants, but initiation or resumption of antiretroviral therapy (ART) can effectively clear persistent infection. COVID-19 vaccine guidelines reflect these increased risks and recommend prioritization for vaccination and additional booster doses for PWH who are moderately to severely immunocompromised. We recommend continued research and monitoring of PWH with SARS-CoV-2 infection, especially in areas with a high HIV burden.
@article{Hoft2023,
abstract = {This review examines the intersection of the HIV and SARS-CoV-2 pandemics. People with HIV (PWH) are a heterogeneous group that differ in their degree of immune suppression, immune reconstitution, and viral control. While COVID-19 in those with well-controlled HIV infection poses no greater risk than that for HIV-uninfected individuals, people with advanced HIV disease are more vulnerable to poor COVID-19 outcomes. COVID-19 vaccines are effective and well tolerated in the majority of PWH, though reduced vaccine efficacy, breakthrough infections and faster waning of vaccine effectiveness have been demonstrated in PWH. This is likely a result of suboptimal humoral and cellular immune responses after vaccination. People with advanced HIV may also experience prolonged infection that may give rise to new epidemiologically significant variants, but initiation or resumption of antiretroviral therapy (ART) can effectively clear persistent infection. COVID-19 vaccine guidelines reflect these increased risks and recommend prioritization for vaccination and additional booster doses for PWH who are moderately to severely immunocompromised. We recommend continued research and monitoring of PWH with SARS-CoV-2 infection, especially in areas with a high HIV burden.},
author = {H{\"{o}}ft, Maxine A and Burgers, Wendy A and Riou, Catherine},
doi = {10.1038/s41423-023-01087-w},
file = {:C$\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/H{\"{o}}ft, Burgers, Riou - 2023 - The immune response to SARS-CoV-2 in people with HIV.pdf:pdf},
issn = {2042-0226},
journal = {Cellular {\&} Molecular Immunology},
keywords = {Cellular immunity,Humoral immunity,OA,Prolonged infection,SARS-CoV-2,Vaccine efficacy,Viral infection,fund{\_}not{\_}ack,review},
mendeley-tags = {OA,fund{\_}not{\_}ack,review},
month = {oct},
pages = {1--13},
pmid = {37821620},
publisher = {Nature Publishing Group},
title = {{The immune response to SARS-CoV-2 in people with HIV}},
url = {https://www.nature.com/articles/s41423-023-01087-w},
year = {2023}
}
Downloads: 0
{"_id":"hv7nXvKDyLPooQm9E","bibbaseid":"hft-burgers-riou-theimmuneresponsetosarscov2inpeoplewithhiv-2023","author_short":["Höft, M. A","Burgers, W. A","Riou, C."],"bibdata":{"bibtype":"article","type":"article","abstract":"This review examines the intersection of the HIV and SARS-CoV-2 pandemics. People with HIV (PWH) are a heterogeneous group that differ in their degree of immune suppression, immune reconstitution, and viral control. While COVID-19 in those with well-controlled HIV infection poses no greater risk than that for HIV-uninfected individuals, people with advanced HIV disease are more vulnerable to poor COVID-19 outcomes. COVID-19 vaccines are effective and well tolerated in the majority of PWH, though reduced vaccine efficacy, breakthrough infections and faster waning of vaccine effectiveness have been demonstrated in PWH. This is likely a result of suboptimal humoral and cellular immune responses after vaccination. People with advanced HIV may also experience prolonged infection that may give rise to new epidemiologically significant variants, but initiation or resumption of antiretroviral therapy (ART) can effectively clear persistent infection. COVID-19 vaccine guidelines reflect these increased risks and recommend prioritization for vaccination and additional booster doses for PWH who are moderately to severely immunocompromised. We recommend continued research and monitoring of PWH with SARS-CoV-2 infection, especially in areas with a high HIV burden.","author":[{"propositions":[],"lastnames":["Höft"],"firstnames":["Maxine","A"],"suffixes":[]},{"propositions":[],"lastnames":["Burgers"],"firstnames":["Wendy","A"],"suffixes":[]},{"propositions":[],"lastnames":["Riou"],"firstnames":["Catherine"],"suffixes":[]}],"doi":"10.1038/s41423-023-01087-w","file":":C$\\$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Höft, Burgers, Riou - 2023 - The immune response to SARS-CoV-2 in people with HIV.pdf:pdf","issn":"2042-0226","journal":"Cellular & Molecular Immunology","keywords":"Cellular immunity,Humoral immunity,OA,Prolonged infection,SARS-CoV-2,Vaccine efficacy,Viral infection,fund_not_ack,review","mendeley-tags":"OA,fund_not_ack,review","month":"oct","pages":"1–13","pmid":"37821620","publisher":"Nature Publishing Group","title":"The immune response to SARS-CoV-2 in people with HIV","url":"https://www.nature.com/articles/s41423-023-01087-w","year":"2023","bibtex":"@article{Hoft2023,\r\nabstract = {This review examines the intersection of the HIV and SARS-CoV-2 pandemics. People with HIV (PWH) are a heterogeneous group that differ in their degree of immune suppression, immune reconstitution, and viral control. While COVID-19 in those with well-controlled HIV infection poses no greater risk than that for HIV-uninfected individuals, people with advanced HIV disease are more vulnerable to poor COVID-19 outcomes. COVID-19 vaccines are effective and well tolerated in the majority of PWH, though reduced vaccine efficacy, breakthrough infections and faster waning of vaccine effectiveness have been demonstrated in PWH. This is likely a result of suboptimal humoral and cellular immune responses after vaccination. People with advanced HIV may also experience prolonged infection that may give rise to new epidemiologically significant variants, but initiation or resumption of antiretroviral therapy (ART) can effectively clear persistent infection. COVID-19 vaccine guidelines reflect these increased risks and recommend prioritization for vaccination and additional booster doses for PWH who are moderately to severely immunocompromised. We recommend continued research and monitoring of PWH with SARS-CoV-2 infection, especially in areas with a high HIV burden.},\r\nauthor = {H{\\\"{o}}ft, Maxine A and Burgers, Wendy A and Riou, Catherine},\r\ndoi = {10.1038/s41423-023-01087-w},\r\nfile = {:C$\\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/H{\\\"{o}}ft, Burgers, Riou - 2023 - The immune response to SARS-CoV-2 in people with HIV.pdf:pdf},\r\nissn = {2042-0226},\r\njournal = {Cellular {\\&} Molecular Immunology},\r\nkeywords = {Cellular immunity,Humoral immunity,OA,Prolonged infection,SARS-CoV-2,Vaccine efficacy,Viral infection,fund{\\_}not{\\_}ack,review},\r\nmendeley-tags = {OA,fund{\\_}not{\\_}ack,review},\r\nmonth = {oct},\r\npages = {1--13},\r\npmid = {37821620},\r\npublisher = {Nature Publishing Group},\r\ntitle = {{The immune response to SARS-CoV-2 in people with HIV}},\r\nurl = {https://www.nature.com/articles/s41423-023-01087-w},\r\nyear = {2023}\r\n}\r\n","author_short":["Höft, M. A","Burgers, W. A","Riou, C."],"key":"Hoft2023","id":"Hoft2023","bibbaseid":"hft-burgers-riou-theimmuneresponsetosarscov2inpeoplewithhiv-2023","role":"author","urls":{"Paper":"https://www.nature.com/articles/s41423-023-01087-w"},"keyword":["Cellular immunity","Humoral immunity","OA","Prolonged infection","SARS-CoV-2","Vaccine efficacy","Viral infection","fund_not_ack","review"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://drive.google.com/uc?export=download&id=1-JLqZ7RwZ3VC2d6ErLGHAtOeMRS_7GCz","dataSources":["Krmt6gt9ktB2s6ARh"],"keywords":["cellular immunity","humoral immunity","oa","prolonged infection","sars-cov-2","vaccine efficacy","viral infection","fund_not_ack","review"],"search_terms":["immune","response","sars","cov","people","hiv","höft","burgers","riou"],"title":"The immune response to SARS-CoV-2 in people with HIV","year":2023}